6-Azauracil derivatives as thyroid receptor ligands
    10.
    发明授权
    6-Azauracil derivatives as thyroid receptor ligands 失效
    6-氮尿嘧啶衍生物作为甲状腺受体配体

    公开(公告)号:US06787652B1

    公开(公告)日:2004-09-07

    申请号:US09671668

    申请日:2000-09-27

    IPC分类号: C07D253075

    摘要: The present invention provides novel compounds of the Formula I and prodrugs thereof, geometric and optical isomers thereof, and pharmaceutically acceptable salts of such compounds, prodrugs and isomers, wherein R1 to R8 and W are as described herein. Pharmaceutical compositions containing such compounds, prodrugs, isomers or pharmaceutically acceptable salts thereof, and methods, pharmaceutical compositions and kits for treating obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure are also provided.

    摘要翻译: 本发明提供式I及其前药的新颖化合物,其几何和旋光异构体,以及这些化合物,前药和异构体的药学上可接受的盐,其中R 1至R 8和W如本文所述。 含有这些化合物,前体药物,异构体或其药学上可接受的盐的药物组合物,以及用于治疗肥胖,超重状况,高脂血症,甲状腺功能减退,甲状腺癌和相关疾病以及疾病如糖尿病,动脉粥样硬化, 还提供高血压,冠心病,高胆固醇血症,抑郁症,骨质疏松症,心律失常,青光眼和充血性心力衰竭。